Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

KIAA1549

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

KIAA1549-BRAF fusion	Astrocytoma	KIAA1549-BRAF fusion	Astrocytoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
KIAA1549-BRAF fusion	Glioma	KIAA1549-BRAF fusion	Glioma	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
KIAA1549-BRAF fusion	Glioma	KIAA1549-BRAF fusion	Glioma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
KIAA1549-BRAF fusion	Soft Tissue Sarcoma	KIAA1549-BRAF fusion	Soft Tissue Sarcoma	bevacizumab + sorafenib + temsirolimus Sensitive: C3 – Early Trials bevacizumab + sorafenib + temsirolimus Sensitive : C3	bevacizumab + sorafenib + temsirolimus Sensitive: C3 – Early Trials bevacizumab + sorafenib + temsirolimus Sensitive : C3
KIAA1549-BRAF fusion	Glioma	KIAA1549-BRAF fusion	Glioma	luvometinib Sensitive: C3 – Early Trials luvometinib Sensitive : C3	luvometinib Sensitive: C3 – Early Trials luvometinib Sensitive : C3
KIAA1549-BRAF fusion + PTEN deletion	Spindle Cell Sarcoma	KIAA1549-BRAF fusion + PTEN deletion	Spindle Cell Sarcoma	bevacizumab + sorafenib + temsirolimus Sensitive: C4 – Case Studies bevacizumab + sorafenib + temsirolimus Sensitive : C4	bevacizumab + sorafenib + temsirolimus Sensitive: C4 – Case Studies bevacizumab + sorafenib + temsirolimus Sensitive : C4
KIAA1549-BRAF fusion	Melanoma	KIAA1549-BRAF fusion	Melanoma	trametinib Sensitive: C4 – Case Studies trametinib Sensitive : C4	trametinib Sensitive: C4 – Case Studies trametinib Sensitive : C4
KIAA1549-BRAF fusion	Melanoma	KIAA1549-BRAF fusion	Melanoma	fotemustine Sensitive: C4 – Case Studies fotemustine Sensitive : C4	fotemustine Sensitive: C4 – Case Studies fotemustine Sensitive : C4
KIAA1549-BRAF fusion	Melanoma	KIAA1549-BRAF fusion	Melanoma	bevacizumab + sorafenib + temsirolimus Sensitive: C4 – Case Studies bevacizumab + sorafenib + temsirolimus Sensitive : C4	bevacizumab + sorafenib + temsirolimus Sensitive: C4 – Case Studies bevacizumab + sorafenib + temsirolimus Sensitive : C4
KIAA1549-BRAF fusion	Melanoma	KIAA1549-BRAF fusion	Melanoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
KIAA1549-BRAF fusion + MET amplification	Non Small Cell Lung Cancer	KIAA1549-BRAF fusion + MET amplification	Non Small Cell Lung Cancer	trametinib + dabrafenib + capmatinib Sensitive: C4 – Case Studies trametinib + dabrafenib + capmatinib Sensitive : C4	trametinib + dabrafenib + capmatinib Sensitive: C4 – Case Studies trametinib + dabrafenib + capmatinib Sensitive : C4
KIAA1549-BRAF fusion	Glioma	KIAA1549-BRAF fusion	Glioma	BVD-523 Sensitive: D – Preclinical BVD-523 Sensitive : D	BVD-523 Sensitive: D – Preclinical BVD-523 Sensitive : D